Singapúr - enska - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - measles virus (more attenuated ender's strain) (live); mumps virus (jeryl lynn strain) (live); rubella virus (wistar ra 27/3 strain) (live) - injection, powder, for solution - min 1000 ccid50/0.5 ml - measles virus (more attenuated ender's strain) (live) min 1000 ccid50/0.5 ml; mumps virus (jeryl lynn strain) (live) min 12500 ccid50/0.5ml; rubella virus (wistar ra 27/3 strain) (live) min 1000 ccid50/0.5 ml

Bandaríkin - enska - NLM (National Library of Medicine)

merck sharp & dohme corp. - measles virus strain enders' attenuated edmonston live antigen (unii: mfz8i7277d) (measles virus strain enders' attenuated edmonston live antigen - unii:mfz8i7277d) - measles virus strain enders' attenuated edmonston live antigen 1000 [tcid_50] in 0.5 ml

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis b vaccine, rdna 10 µg/ml - suspension for injection - 10 mcg/ml - active: hepatitis b vaccine, rdna 10 µg/ml excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax formaldehyde potassium thiocyanate sodium chloride water for injection - immunisation against infection caused by all known subtypes of hepatitis b virus. hbvaxpro should also prevent hepatitis d (caused by the delta virus) since hepatitis d does not occur in the absence of hepatitis b infection.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hepatitis b vaccine, rdna 40 µg/ml - suspension for injection - 40 mcg/ml - active: hepatitis b vaccine, rdna 40 µg/ml excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax formaldehyde potassium thiocyanate sodium chloride water for injection - immunisation against infection caused by all known subtypes of hepatitis b virus. hbvaxpro should also prevent hepatitis d (caused by the delta virus) since hepatitis d does not occur in the absence of hepatitis b infection.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - rotavirus reassortant strain g1 2.2e+006 [iu] (nlt, at expiry); rotavirus reassortant strain g2 2.8e+006 [iu] (nlt, at expiry); rotavirus reassortant strain g3 2.2e+006 [iu] (nlt, at expiry); rotavirus reassortant strain g4 2e+006 [iu] (nlt, at expiry); rotavirus reassortant strain p1 2.3e+006 [iu] (nlt, at expiry) - oral solution - 2 ml - active: rotavirus reassortant strain g1 2.2e+006 [iu] (nlt, at expiry) rotavirus reassortant strain g2 2.8e+006 [iu] (nlt, at expiry) rotavirus reassortant strain g3 2.2e+006 [iu] (nlt, at expiry) rotavirus reassortant strain g4 2e+006 [iu] (nlt, at expiry) rotavirus reassortant strain p1 2.3e+006 [iu] (nlt, at expiry) excipient: rotavirus diluent & lpkm-3 (from actives) to approx 0.3 ml. includes animal materials as below. monobasic sodium phosphate monohydrate polysorbate 80 purified water sodium citrate dihydrate sodium hydroxide sucrose - rotateq is an oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes g1, g2, g3, g4, and g-serotypes that contain p1a[8] (e.g., g9). rotateq may be administered as early as six weeks of age.

Nígería - enska - NAFDAC (National Agency for Food and Drugs Administration and Control)

live oral poliovirus vaccine sabian is a combined trivalent vaccine containing s of type 1+2+3 of live attenuated poliomyletis viruses

Singapúr - enska - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - varicella virus vaccine live (oka/merck) - injection - 2700 pfu/ml - varicella virus vaccine live (oka/merck) 2700 pfu/ml

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

astrazeneca uk ltd - influenza virus live attenuated - spray

Bandaríkin - enska - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - measles virus strain schwartz attenuated chick embryo fibroblasts live antigen (unii: yrf2uzg52m) (measles virus strain schwartz attenuated chick embryo fibroblasts live antigen - unii:yrf2uzg52m), mumps virus strain rit-4385 attenuated chick embryo fibroblasts live antigen (unii: 566fj5l8r4) (mumps virus strain rit-4385 attenuated chick embryo fibroblasts live antigen - unii:566fj5l8r4), rubella virus strain wistar ra 27/3 live antigen (unii: 52202h034z) (rubella virus strain wistar ra 27/3 live antigen - unii:52202h034z) - priorix is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older. do not administer priorix to individuals with a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine or after a previous dose of any measles, mumps, and rubella virus-containing vaccine [see description (11)] . due to the risk of disseminated vaccine virus infection, do not administer priorix to individuals with severe humoral or cellular (primary or acquired) immunodeficiency. do not administer priorix to individuals who are pregnant. pregnancy should be avoided for 1 month after vaccination [see use in specific populations (8.1)] . risk summary priorix contains live attenuated measles, mumps, and rubella viruses. the vaccine is contraindicated for use in pregnant women because infection during pregnancy with the wild-type viruses is associated with maternal and fetal adverse outcomes. pregnancy should be avoided for 1 month after vaccination [see contraindications (4.3), patient counseling information (17)]. reports have indicated that contracting wild-type measles during pregnancy enhances fetal risk, including increased rates of spontaneous abortion, stillbirth, premature delivery and congenital defects.2,3 wild-type mumps virus infection during the first trimester of pregnancy may increase the rate of spontaneous abortion. pregnant women infected with wild-type rubella virus are at increased risk for miscarriage or stillbirth, and their infants are at risk for congenital rubella syndrome.1 available data on inadvertent administration of priorix to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. there are no animal studies with priorix to inform use during pregnancy. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary it is not known whether the vaccine components of priorix are excreted in human milk. data are not available to assess the effects of priorix on the breastfed infant or on milk production/excretion. studies have shown that lactating postpartum women vaccinated with live attenuated rubella vaccine may secrete the virus in breast milk and transmit it to breast‑fed infants.4,5 in the breast-fed infants with serological evidence of rubella virus vaccine strain antibodies, none exhibited severe disease; however, one exhibited mild clinical illness typical of acquired rubella.6,7 the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for priorix and any potential adverse effects on the breastfed child from priorix or from the underlying maternal condition. for preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine. safety and effectiveness of priorix in infants younger than 12 months have not been established. clinical studies of priorix did not include participants 65 years of age and older to determine whether they respond differently from younger participants.

Ísrael - enska - Ministry of Health

sanofi israel ltd - poliovirus type 1 inactivated; poliovirus type 2 inactivated; poliovirus type 3 inactivated - suspension for injection - poliovirus type 1 inactivated 40 u/vial; poliovirus type 2 inactivated 8 u/vial; poliovirus type 3 inactivated 32 u/vial - poliomyelitis vaccines - prophylaxis of poliomyelitis.